Synergistic anti-tumor effects of vandetanib, an inhibitor of VEGFR and EGFR tyrosine kinase inhibitor, combined with cytotoxic agents in lung cancer cell lines Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010
Mutations of EGFR and k-ras genes and TK inhibitors. Are there differences between gefitinib and erlotinib? Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008
Targeting of STAT3 and survivin with TG101209, a novel JAK2 inhibitor, enhances radiotherapy in lung cancer models Source: Annual Congress 2010 - New insights in the pathology of lung cancer Year: 2010
Targeting STAT3 pathway signalling in EGFR TKI resistant NSCLC Source: Virtual Congress 2020 – Chronic lung diseases: novel methods, diagnostics and biomarkers Year: 2020
Re-purposing TKI treatment Source: International Congress 2016 – The future of tyrosin kinase inhibitors Year: 2016
Antitumor activity of MEK and PI3K inhibitors in malignant pleural mesothelioma Source: Annual Congress 2011 - Treatment options and tumour biology of malignant pleural mesothelioma Year: 2011
Overcome the EGFR-TKIs resistance with cucurbitacin BE compound by targeting STAT3, ERK1/2 and AKT Source: Annual Congress 2012 - New insights in the pathology of lung cancer Year: 2012
EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice Source: Eur Respir J, 50 (2) 1700514; 10.1183/13993003.00514-2017 Year: 2017
Gefitinib (‘Iressa’, ZD1839) improves disease-related symptoms in NSCLC Source: Eur Respir J 2003; 22: Suppl. 45, 29s Year: 2003
Potential therapeutic significance of CIK cells in gefitinib resistant NSCLC with EGFR mutations Source: Annual Congress 2011 - Progress in pathology of lung cancer Year: 2011
The inhibitory effect of PI3k inhibitor and MEK inhibitor on malignant pleural mesothelioma cell growth Source: Annual Congress 2009 - Pleural and mediastinal diseases Year: 2009
The response to erlotinib third-line treatment in bronchioalveolar carcinoma in the absence of EGFR expression Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009
Synergistic therapy for NSCLC: Additive preclinical efficacy of interleukin-6 inhibitor madindoline A with crizotinib Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012
Met amplification induces an aggressive phenotype in EGFR tyrosine kinase inhibitors resistant non-small-cell lung cancer Source: International Congress 2015 – New frontiers in biomedical research on thoracic tumours Year: 2015
Maintenance treatment with erlotinib after induction chemotherapy for advanced NSCLC Source: Annual Congress 2011 - Recent therapeutic advances with tyrosine-kinase inhibitors in nonsmall-cell lung cancer Year: 2011
The predictive value of circulating tumor DNA dynamics in plasma of EGFR-mutation-positive NSCLC patients on first line tyrosine kinase inhibitors Source: Virtual Congress 2021 – New clinical and biological developments in lung cancer Year: 2021
Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors Source: ERJ Open Res, 3 (3) 00092-2016; 10.1183/23120541.00092-2016 Year: 2017
Effects of mTOR Inhibition in malignant mesothelioma Source: Annual Congress 2010 - Basic mechanisms in malignant pleural disease biology Year: 2010
Comparison of NSCLC patient groups with activated EGFR mutations treated with three different tyrosine-kinase inhibitors (TKI): Real-life data from the Czech Republic Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017